Product
CART-BCMA
3 clinical trials
4 indications
Indication
Multiple MyelomaIndication
Kidney TransplantIndication
Kidney FailureIndication
End Stage Renal Failure on DialysisClinical trial
A Phase I Clinical Trial to Evaluate CART-BCMA in Patients With Relapsed and/or Refractory Multiple MyelomaStatus: Active (not recruiting), Estimated PCD: 2022-07-31
Clinical trial
Pilot Study Of Redirected Autologous T Cells Engineered To Contain an Anti-BCMA scFv Coupled To TCRζ And 4-1BB Signaling Domains in Patients With Relapsed and/or Refractory Multiple MyelomaStatus: Completed, Estimated PCD: 2019-08-21
Clinical trial
Autologous Chimeric Antigen Receptor Engineered T Cell Immunotherapy for Desensitization in Patients Awaiting Kidney TransplantationStatus: Recruiting, Estimated PCD: 2028-12-15